Precision Benefit Design: How should the arrival of precision medicine affect health plan benefit design?
Advances in precision medicine offer the promise of tremendous gains in patient health over the coming decades. Headlines in the popular press as well as discussions at academic conferences tout the potential benefits of precision medicine, while at the same time critiquing the nascent but growing evidence base and the high cost of treatment. One […]
Is One Answer Good Enough for All? Defining Value in Healthcare
While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI’s Jennifer Bright and Mark Linthicum address this concern in a recent article for the American Journal of Managed Care (AJMC). Read the […]
IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making
CVS Health’s pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI’s Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, “The neat ‘answer’ regarding the value of treatment […]
Why Quality Measures Must Reflect Patient Values, Care Experience
There isn’t an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI’s Jennifer Bright (Executive Director) and Mark Linthicum (Director […]
Is Using Centralized Value Assessment to Make Centralized Pricing Decisions the Most Effective Path Forward?
The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and needed, IVI cautions about making centralized pricing decisions based on centralized value assessments within the U.S.’s current decentralized health care […]
IVI Leadership Invited to Speak at the 2018 BIO International Convention
The 2018 BIO International Convention will be held in Boston, MA from June 4th through June 7th. IVI’s Jennifer Bright (Acting Executive Director) and Mark Linthicum (Director of Scientific Communications) are among the speakers invited to the 2018 BIO International Convention, where they will be discussing value assessment frameworks and patient value. The description of […]
IVI Demonstrates Commitment to Patient Involvement with Release of “Partnering with Patients” Principles
To demonstrate IVI’s commitment to patient involvement and ensure that the patient perspective is represented in our work, IVI recently developed several documents enumerating the principles and practices that guide this vital partnership. These documents offer detail about the actions IVI takes to involve patients and patient organizations early and often in research, model development and other projects, and establish a basis […]
IVI-RA Value Tool Featured on ISPOR Student Webinar Series
Devin Incerti, Lead Economist on IVI’s Open-Source Value Project, will be presenting the IVI-RA Value Tool as one of ISPOR’s featured student webinars. See below for the full description and details on the webinar, as well as the registration link. WEBINAR: Developing Flexible, Iterative, and Transparent Decision Models: A Detailed Look at the Rheumatoid Arthritis […]